carmustine has been researched along with Central Nervous System Neoplasm in 43 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy combined with radiotherapy (RT) for patients with non-AIDS-related primary CNS lymphoma (PCNSL) treated in a multicenter setting." | 9.10 | High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. ( Fickers, M; Haaxma-Reiche, H; Hansen, M; Kluin-Nelemans, HC; Poortmans, PM; Rozewicz, C; Soubeyran, P; Taphoorn, M; Teodorovic, I; Thomas, J; Van den Bent, M; van Glabbeke, M; Van Imhoff, G; Van't Veer, M, 2003) |
| "To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy combined with radiotherapy (RT) for patients with non-AIDS-related primary CNS lymphoma (PCNSL) treated in a multicenter setting." | 5.10 | High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. ( Fickers, M; Haaxma-Reiche, H; Hansen, M; Kluin-Nelemans, HC; Poortmans, PM; Rozewicz, C; Soubeyran, P; Taphoorn, M; Teodorovic, I; Thomas, J; Van den Bent, M; van Glabbeke, M; Van Imhoff, G; Van't Veer, M, 2003) |
| "To assess the effect of a reduced dose of radiotherapy (RT) in patients with primary CNS lymphoma (PCNSL) responding to the cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD)/carmustine, vincristine, methotrexate, and cytarabine (BVAM) regimen." | 5.10 | Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. ( Bessell, EM; Byrne, P; Graus, F; López-Guillermo, A; Montserrat, E; Nomdedeu, B; Petit, J; Verger, E; Villá, S, 2002) |
| " Preclinical and phase I trials have shown the additive or synergistic activity of temozolomide combined with carmustine against solid tumors, including malignant glioma, and the sequence-dependent effects of the combination." | 4.81 | Temozolomide in combination with other cytotoxic agents. ( Prados, M, 2001) |
| "Carmustine (BCNU) is a cytotoxic drug which is a recognized cause of acute pulmonary fibrosis." | 3.68 | Chronic lung fibrosis following carmustine (BCNU) chemotherapy: radiological features. ( Gattamaneni, HR; O'Driscoll, BR; Taylor, PM; Woodcock, AA, 1991) |
| "Twenty-three patients were treated (22 with glioblastoma multiforme and one with anaplastic astrocytoma)." | 2.69 | Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ( Ashley, DM; Bigner, DD; Cokgor, I; Colvin, OM; Dolan, ME; Ewesuedo, RB; Friedman, AH; Friedman, HS; Garcia-Turner, AM; Haglund, MM; Herndon, JE; Long, L; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, J; Stewart, ES; Tourt-Uhlig, S, 2000) |
| "Malignant gliomas are very difficult neoplasms for clinicians to treat." | 2.44 | Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. ( Bohan, E; Brem, H; Hussain, N; Kleinberg, L; Lawson, HC; Olivi, A; Park, MC; Sampath, P; Weingart, J, 2007) |
| " Pretreatment of mice with O6-benzylguanine increased temozolomide-induced mortality, requiring reduction of the dosage from 1200 to 750 mg/m2 on the single-day regimen." | 1.29 | Activity of temozolomide in the treatment of central nervous system tumor xenografts. ( Bigner, DD; Catino, JJ; Dolan, ME; Friedman, HS; Keir, S; Marcelli, S; Pegg, AE; Schold, SC, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 25 (58.14) | 29.6817 |
| 2010's | 7 (16.28) | 24.3611 |
| 2020's | 7 (16.28) | 2.80 |
| Authors | Studies |
|---|---|
| Reiss, SN | 1 |
| Yerram, P | 1 |
| Modelevsky, L | 1 |
| Grommes, C | 1 |
| Schenone, L | 1 |
| Houillier, C | 1 |
| Tanguy, ML | 1 |
| Choquet, S | 1 |
| Agbetiafa, K | 1 |
| Ghesquières, H | 1 |
| Damaj, G | 2 |
| Schmitt, A | 1 |
| Bouabdallah, K | 1 |
| Ahle, G | 1 |
| Gressin, R | 1 |
| Cornillon, J | 1 |
| Houot, R | 1 |
| Marolleau, JP | 1 |
| Fornecker, LM | 1 |
| Chinot, O | 1 |
| Peyrade, F | 1 |
| Bouabdallah, R | 1 |
| Moluçon-Chabrot, C | 1 |
| Gyan, E | 1 |
| Chauchet, A | 1 |
| Casasnovas, O | 1 |
| Oberic, L | 1 |
| Delwail, V | 2 |
| Abraham, J | 1 |
| Roland, V | 1 |
| Waultier-Rascalou, A | 1 |
| Willems, L | 1 |
| Morschhauser, F | 1 |
| Fabbro, M | 1 |
| Ursu, R | 1 |
| Thieblemont, C | 1 |
| Jardin, F | 1 |
| Tempescul, A | 1 |
| Malaise, D | 1 |
| Touitou, V | 1 |
| Nichelli, L | 1 |
| Le Garff-Tavernier, M | 1 |
| Plessier, A | 1 |
| Bourget, P | 1 |
| Bonmati, C | 1 |
| Wantz-Mézières, S | 1 |
| Giordan, Q | 1 |
| Dorvaux, V | 1 |
| Charron, C | 1 |
| Jabeur, W | 1 |
| Hoang-Xuan, K | 1 |
| Taillandier, L | 1 |
| Soussain, C | 1 |
| Arshad, S | 1 |
| Fang, X | 1 |
| Ahn, KW | 1 |
| Kaur, M | 1 |
| Scordo, M | 1 |
| Sauter, CS | 1 |
| Furqan, F | 1 |
| Awan, FT | 1 |
| Hamadani, M | 1 |
| Velasco, R | 1 |
| Mercadal, S | 1 |
| Vidal, N | 1 |
| Alañá, M | 1 |
| Barceló, MI | 1 |
| Ibáñez-Juliá, MJ | 1 |
| Bobillo, S | 1 |
| Caldú Agud, R | 1 |
| García Molina, E | 1 |
| Martínez, P | 1 |
| Cacabelos, P | 1 |
| Muntañola, A | 1 |
| García-Catalán, G | 1 |
| Sancho, JM | 1 |
| Camro, I | 1 |
| Lado, T | 1 |
| Erro, ME | 1 |
| Gómez-Vicente, L | 1 |
| Salar, A | 1 |
| Caballero, AC | 1 |
| Solé-Rodríguez, M | 1 |
| Gállego Pérez-Larraya, J | 1 |
| Huertas, N | 1 |
| Estela, J | 1 |
| Barón, M | 1 |
| Barbero-Bordallo, N | 1 |
| Encuentra, M | 1 |
| Dlouhy, I | 1 |
| Bruna, J | 1 |
| Graus, F | 4 |
| Khurana, A | 1 |
| Micallef, IN | 1 |
| LaPlant, BR | 1 |
| Patrick O'Neill, B | 1 |
| Habermann, TM | 2 |
| Ansell, SM | 1 |
| Inwards, DJ | 1 |
| Porrata, LF | 2 |
| Paludo, J | 1 |
| Bisneto, JCV | 1 |
| Johnston, PB | 1 |
| Steinhardt, MJ | 1 |
| Krummenast, FC | 1 |
| Rosenwald, A | 1 |
| Gerhard-Hartmann, E | 1 |
| Heidemeier, A | 1 |
| Einsele, H | 1 |
| Topp, MS | 1 |
| Duell, J | 1 |
| Kaji, FA | 1 |
| Martinez-Calle, N | 1 |
| Bishton, MJ | 1 |
| Figueroa, R | 1 |
| Adlington, J | 1 |
| O'Donoghue, M | 1 |
| Smith, S | 1 |
| Byrne, P | 3 |
| Paine, S | 1 |
| Sovani, V | 1 |
| Auer, D | 1 |
| James, E | 1 |
| Bessell, EM | 4 |
| Grainge, MJ | 1 |
| Fox, CP | 1 |
| Lillehei, KO | 1 |
| Kalkanis, SN | 1 |
| Liau, LM | 1 |
| Mydland, DE | 1 |
| Olson, J | 1 |
| Paleologos, NA | 1 |
| Ryken, T | 1 |
| Johnson, T | 1 |
| Scullin, E | 1 |
| Burnette, BL | 1 |
| Jentoft, MA | 1 |
| Boyce, TG | 1 |
| Witzig, TE | 1 |
| Bojic, M | 1 |
| Berghoff, AS | 1 |
| Troch, M | 1 |
| Agis, H | 1 |
| Sperr, WR | 1 |
| Widhalm, G | 1 |
| Wöhrer, A | 1 |
| Kalhs, P | 1 |
| Preusser, M | 1 |
| Rabitsch, W | 1 |
| Illerhaus, G | 3 |
| Kasenda, B | 2 |
| Ihorst, G | 2 |
| Egerer, G | 1 |
| Lamprecht, M | 1 |
| Keller, U | 1 |
| Wolf, HH | 1 |
| Hirt, C | 1 |
| Stilgenbauer, S | 1 |
| Binder, M | 1 |
| Hau, P | 1 |
| Edinger, M | 1 |
| Frickhofen, N | 2 |
| Bentz, M | 1 |
| Möhle, R | 1 |
| Röth, A | 1 |
| Pfreundschuh, M | 1 |
| von Baumgarten, L | 1 |
| Deckert, M | 1 |
| Hader, C | 1 |
| Fricker, H | 1 |
| Valk, E | 1 |
| Schorb, E | 2 |
| Fritsch, K | 2 |
| Finke, J | 3 |
| Vinjamuri, M | 1 |
| Adumala, RR | 1 |
| Altaha, R | 1 |
| Hobbs, GR | 1 |
| Crowell, EB | 1 |
| Laack, NN | 1 |
| O'Neill, BP | 1 |
| Ballman, KV | 1 |
| O'Fallon, JR | 1 |
| Carrero, XW | 1 |
| Kurtin, PJ | 1 |
| Scheithauer, BW | 1 |
| Brown, PD | 1 |
| Colgan, JP | 1 |
| Gilbert, MR | 1 |
| Hawkins, RB | 1 |
| Morton, RF | 1 |
| Windschitl, HE | 1 |
| Fitch, TR | 1 |
| Pajon, ER | 1 |
| Waibel Pachinger, C | 1 |
| Rosselet, A | 1 |
| Berthouzoz, S | 1 |
| Luthi, F | 1 |
| Ketterer, N | 1 |
| Friedman, HS | 4 |
| Keir, S | 2 |
| Pegg, AE | 4 |
| Houghton, PJ | 1 |
| Colvin, OM | 2 |
| Moschel, RC | 3 |
| Bigner, DD | 4 |
| Dolan, ME | 4 |
| Seong, H | 1 |
| An, TK | 1 |
| Khang, G | 1 |
| Choi, SU | 1 |
| Lee, CO | 1 |
| Lee, HB | 1 |
| Poortmans, PM | 1 |
| Kluin-Nelemans, HC | 2 |
| Haaxma-Reiche, H | 2 |
| Van't Veer, M | 1 |
| Hansen, M | 1 |
| Soubeyran, P | 1 |
| Taphoorn, M | 1 |
| Thomas, J | 1 |
| Van den Bent, M | 1 |
| Fickers, M | 1 |
| Van Imhoff, G | 1 |
| Rozewicz, C | 1 |
| Teodorovic, I | 1 |
| van Glabbeke, M | 1 |
| Abrey, LE | 1 |
| Moskowitz, CH | 1 |
| Mason, WP | 1 |
| Crump, M | 1 |
| Stewart, D | 1 |
| Forsyth, P | 1 |
| Paleologos, N | 1 |
| Correa, DD | 1 |
| Anderson, ND | 1 |
| Caron, D | 1 |
| Zelenetz, A | 1 |
| Nimer, SD | 1 |
| DeAngelis, LM | 1 |
| Harder, H | 1 |
| Holtel, H | 1 |
| Bromberg, JE | 1 |
| Poortmans, P | 1 |
| Menten, J | 1 |
| van den Bent, MJ | 1 |
| Lopez-Guillermo, A | 3 |
| Lewis, SA | 1 |
| Villa, S | 3 |
| Verger, E | 3 |
| Petit, J | 3 |
| Lustig, RA | 1 |
| Scott, CB | 1 |
| Curran, WJ | 1 |
| Korfel, A | 2 |
| Martus, P | 1 |
| Nowrousian, MR | 1 |
| Hossfeld, DK | 1 |
| Kirchen, H | 1 |
| Brücher, J | 1 |
| Stelljes, M | 1 |
| Birkmann, J | 1 |
| Peschel, C | 1 |
| Pasold, R | 1 |
| Fischer, L | 1 |
| Jahnke, K | 1 |
| Thiel, E | 2 |
| Webster, M | 1 |
| Cairncross, G | 1 |
| Gertler, S | 1 |
| Perry, J | 1 |
| Wainman, N | 1 |
| Eisenhauer, E | 1 |
| Brevet, M | 1 |
| Garidi, R | 1 |
| Gruson, B | 1 |
| Royer, B | 1 |
| Vaida, I | 1 |
| Reardon, DA | 1 |
| Marks, R | 1 |
| Guttenberger, R | 1 |
| Ostertag, C | 1 |
| Derigs, G | 1 |
| Feuerhake, F | 1 |
| Volk, B | 1 |
| Colombat, P | 1 |
| Lemevel, A | 1 |
| Bertrand, P | 1 |
| Rachieru, P | 1 |
| Brion, A | 1 |
| Berthou, C | 1 |
| Bay, JO | 1 |
| Delepine, R | 1 |
| Desablens, B | 1 |
| Camilleri-Broët, S | 1 |
| Linassier, C | 1 |
| Lamy, T | 1 |
| Lawson, HC | 1 |
| Sampath, P | 1 |
| Bohan, E | 1 |
| Park, MC | 1 |
| Hussain, N | 1 |
| Olivi, A | 1 |
| Weingart, J | 1 |
| Kleinberg, L | 1 |
| Brem, H | 1 |
| Adams, DM | 1 |
| Zhou, T | 1 |
| Berg, SL | 1 |
| Bernstein, M | 1 |
| Neville, K | 1 |
| Blaney, SM | 1 |
| Gill, P | 1 |
| Litzow, M | 1 |
| Buckner, J | 1 |
| Arndt, C | 1 |
| Moynihan, T | 1 |
| Christianson, T | 1 |
| Ansell, S | 1 |
| Galanis, E | 1 |
| Marcelli, S | 1 |
| Catino, JJ | 1 |
| Schold, SC | 1 |
| Cheng, AL | 1 |
| Yeh, KH | 1 |
| Uen, WC | 1 |
| Hung, RL | 1 |
| Liu, MY | 1 |
| Wang, CH | 1 |
| Keir, ST | 1 |
| Lawless, A | 1 |
| Alvarnas, JC | 1 |
| Negrin, RS | 1 |
| Horning, SJ | 1 |
| Hu, WW | 1 |
| Long, GD | 1 |
| Schriber, JR | 1 |
| Stockerl-Goldstein, K | 1 |
| Tierney, K | 1 |
| Wong, R | 1 |
| Blume, KG | 1 |
| Chao, NJ | 1 |
| Papadakis, V | 1 |
| Dunkel, IJ | 1 |
| Cramer, LD | 1 |
| Kramer, E | 1 |
| Papadopoulos, E | 1 |
| Goldman, S | 1 |
| Packer, RJ | 1 |
| Willoughby, M | 1 |
| Baker, D | 1 |
| Garvin, J | 1 |
| Strandjord, S | 1 |
| Coccia, P | 1 |
| Kaplan, AM | 1 |
| Klemperer, M | 1 |
| Finlay, JL | 1 |
| Pluda, J | 1 |
| Quinn, JA | 1 |
| Ewesuedo, RB | 1 |
| Long, L | 1 |
| Friedman, AH | 1 |
| Cokgor, I | 1 |
| Haglund, MM | 1 |
| Ashley, DM | 1 |
| Rich, JN | 1 |
| Sampson, J | 1 |
| McLendon, RE | 1 |
| Provenzale, JM | 1 |
| Stewart, ES | 1 |
| Tourt-Uhlig, S | 1 |
| Garcia-Turner, AM | 1 |
| Herndon, JE | 1 |
| Holland, I | 1 |
| Prados, M | 1 |
| Nomdedeu, B | 1 |
| Montserrat, E | 1 |
| Goldkuhl, C | 1 |
| Ekman, T | 1 |
| Wiklund, T | 1 |
| Telhaug, R | 1 |
| Taylor, PM | 1 |
| O'Driscoll, BR | 1 |
| Gattamaneni, HR | 1 |
| Woodcock, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studio Osservazionale Retrospettivo Multicentrico Sull'Utilizzo di Ibrutinib in Monoterapia o in Associazione a Immunochemioterapia Secondo Schema R-CHOP in Pazienti Adulti Con Diagnosi di PCNSL Ricaduto o Refrattario[NCT05782374] | 36 participants (Anticipated) | Observational | 2022-08-10 | Recruiting | |||
| Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice[NCT02684838] | 272 participants (Actual) | Observational | 2016-04-26 | Active, not recruiting | |||
| Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation[NCT00647049] | Phase 2 | 78 participants (Anticipated) | Interventional | 2007-01-31 | Recruiting | ||
| PHASE II TRIAL OF CHEMOTHERAPY PLUS RADIOTHERAPY FOR MANAGEMENT OF PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN'S LYMPHOMA (PCNSL)[NCT00002676] | Phase 2 | 36 participants (Actual) | Interventional | 1995-07-31 | Completed | ||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)[NCT00003061] | Phase 2 | 50 participants (Anticipated) | Interventional | 1997-07-31 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma[NCT00036660] | Phase 2 | 10 participants (Actual) | Interventional | 2002-01-10 | Completed | ||
| A Trial of 06-BG and BCNU in Children With CNS Tumors[NCT00003765] | Phase 1 | 36 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
3 reviews available for carmustine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2015 |
Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Decanoic A | 2007 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neo | 2001 |
14 trials available for carmustine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous | 2016 |
Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combined Modality T | 2009 |
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2011 |
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous | 2003 |
Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2005 |
Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Astrocytoma; Canada; Carbon Monoxide; | 2005 |
First-line autologous stem cell transplantation in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2005 |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Central Nervous Syst | 2000 |
CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2001 |
Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central | 2002 |
Age-adjusted chemotherapy for primary central-nervous system lymphoma--a pilot study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervou | 2002 |
26 other studies available for carmustine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System; Central Ne | 2022 |
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra | 2022 |
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Central Nervous Syste | 2023 |
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central | 2020 |
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System; Central Nervous | 2020 |
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2022 |
Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous Syste | 2021 |
Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carmustine; Central Nervous System Neoplasms; Decanoic Aci | 2018 |
Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biops | 2014 |
Acute coronary syndrome upon receiving carmustine infusion before autologous stem-cell transplantation.
Topics: Acute Coronary Syndrome; Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neopl | 2012 |
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2012 |
O6-benzylguanine-mediated enhancement of chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Camptothecin; Carmustine; Central | 2002 |
BCNU-loaded poly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Drug Carriers; Drug | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Cognitive status and quality of life after treatment for primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Carmustine; Case-Control Stud | 2004 |
Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Centr | 2004 |
Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combin | 2004 |
Glioblastoma--more questions than answers?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carmustine; Central Nervous System Neoplasms; Combined Mod | 2006 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2008 |
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Topics: Animals; Carmustine; Central Nervous System Neoplasms; Dacarbazine; Female; Guanine; Humans; Male; M | 1995 |
Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 1998 |
Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Carmustine; Centra | 1998 |
O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.
Topics: Animals; Antineoplastic Agents; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Top | 2000 |
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carm | 2000 |
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 2000 |
Chronic lung fibrosis following carmustine (BCNU) chemotherapy: radiological features.
Topics: Carmustine; Central Nervous System Neoplasms; Child; Humans; Pulmonary Fibrosis; Time Factors; Tomog | 1991 |